Zerona Additional Benefits

Erchonia Medical, the global leader in low level laser healthcare applications, announces today that its newest laser for body sculpting, Zerona, has been clinically shown to reduce the levels of the hunger-hormone, leptin, and lipoprotein (LDL).   A 22 participant pilot study revealed that Zerona not only reduced circumferential inches following a two week treatment phase, but also lowered all patients’ leptin levels and reduced low-density lipoprotein numbers in over 50% of the participants in just two weeks.

Although Zerona is already positioned ahead of its competitors in terms of its ability to non-invasively, safely and effectively reduce an average of 3.64 inches around the waist, hips and thighs, this new data could have beneficial results for many patients struggling with overeating. Suppressing the very hormones that may cause individuals to be overweight or obese can further aid Zerona patients with their weight-loss goals.

Erchonia President, Steve Shanks, comments, “For most devices, the patient comes in, receives the treatment and leaves; the reason why that person was overweight or obese to begin with is not addressed. By suppressing the hunger-hormone leptin, patients’ appetites can be lessened helping them modify their diets and establish portion control going forward.”

In addition to reducing inches, suppressing hunger and reducing LDL levels, Zerona is also unique because it does not destroy fat tissue, unlike the majority of other devices on the market.  The Zerona promotes a biological cascade within the cells provoking the formation of tiny pore or opening within the lipid membrane. The stored fatty material then leaves the cell, causing it to collapse safely.

For more information on the Zerona laser, please visit www.myzerona.com.

Erchonia is the global leader in low level laser healthcare applications. Over the last 15 years Erchonia has been conducting research & development with the world’s leading physicians to advance the science of low level lasers. Prior to market introduction, all Erchonia lasers are proven to be safe and effective through independent clinical trials. Currently thousands of Erchonia’s lasers are used daily to reduce body fat, eliminate pain, accelerate healing, and treat acne. For additional information, visit www.erchonia.com

– Erchonia, the global leader in low level laser healthcare applications, presents three new studies at the upcoming American Society for Laser Medicine and Surgery Annual Conference this week in Phoenix, Arizona.Erchonia will be presenting a study it conducted using low level lasers to treat late stage Parkinson’s disease. Eight volunteers between 18 and 80 years with late stage PD participated in the non-controlled, non-randomized study and received low level laser treatments daily for two weeks. Patients were asked to rate the severity of their symptoms (balance, gait, freezing, cognitive function, rolling in bed, and speech difficulties) from 0 to 10 using the Visual Analog Scale. All participants demonstrated a decrease in VAS from baseline to study endpoint.The second study Erchonia plans to present shows how low-level lasers may reduce low-density lipoprotein levels (LDL). Forty one patients between 18 and 65 years participated in the non-controlled, non-randomized study. Partipants received a 40-minute ZERONA laser treatment three times a week for two weeks and demonstrated a reduction in low-density lipoprotein levels of 12.05 points, a 13% reduction. This study suggests that low level laser therapy may serve as a non-invasive way to reduce LDL levels in two weeks.Erchonia’s third study explores how its ZERONA laser impacts leptin levels, the hormone linked to hunger. Twenty volunteers between the ages of 18 and 65 participated in Erchonia’s non-controlled, non-randomized study. Participants received 40-minute ZERONA low-level laser treatments, three times per week for two weeks. All participants demonstrated a reduction in leptin levels compared to their baseline – on average, a 50% decrease. Since leptin levels are associated with hunger, this study shows how low level laser technology may noninvasively suppress the appetite.

Ryan Maloney, Erchonia’s medical director and one of the authors of the studies comments, “Although these were non-controlled, non-randomized pilot studies, they each showed promising new applications for low level laser technology. Further study is needed, but Erchonia is paving the way for new noninvasive healthcare technologies with a commitment to research and innovation.”